Tamtam Try Tamtam free
Viatris logo

Viatris account plan

Extensive medicine portfolio supply

At a glance

Viatris is a global healthcare company selling generics, established brands and innovative medicines in 165 countries, with $14.25 billion 2025 net sales.

Viatris is a global healthcare company formed in November 2020 from Mylan and Pfizer's Upjohn Business, with global centers in Pittsburgh, Shanghai and Hyderabad. It sells generics (including complex products such as Breyna and estradiol patches), established brands such as Lipitor, Norvasc, Lyrica and Viagra, and a growing innovative medicines portfolio to pharmacies, wholesalers, payers, governments and hospitals in more than 165 countries and territories. In 2025 total revenues were $14,299.9 million (down 3%), with a net loss of $3,514.9 million after a $2.94 billion goodwill impairment and adjusted EBITDA of $4,160.0 million. It has more than 30,000 employees and 27 manufacturing, packaging and distribution sites, and is listed in the U.S.

Business units

Strategic priorities

2030 growth targets
5%-6% total revenue growth, 7%-8% adjusted EBITDA growth, 9%-10% adjusted EPS growth and more than $3 billion a year of free cash flow by 2030.
Enterprise-wide strategic review savings
A workforce reduction of up to approximately 10%, with pre-tax charges of $700 million to $850 million, targeting approximately $400 million of net cost savings split between COGS and SG&A, overseen by a transformation office.
Innovative portfolio
Fast-acting meloxicam (PDUFA date December 27), cenerimod and selatogrel readouts in the first half of 2027, and new launches such as Gwyn Lo and RYZUMVI; cenerimod and selatogrel peak sales are estimated at over $1 billion each.
Complex generics and first-to-market
Viatris plans generics for molecules representing about 70% of a $107 billion non-biologic patent cliff (2025-2030) and expects over 100 new generic approvals this year.
Business development as a platform
Targeting $1 billion-$1.5 billion of incremental revenue and $500 million of EBITDA over five years through regional licensing and small to mid-size M&A of in-market products, mainly in the U.S., Japan and China.

Latest results

Q3 2026 total revenues were $3,749.5 million, flat against $3,759.9 million a year earlier, as new products and growth in North America and Greater China offset supply constraints in Europe and Emerging Markets. Adjusted EBITDA rose 4% to $1,195.7 million and adjusted EPS to $0.71, while the GAAP net loss was $325.3 million because of a higher tax provision. Free cash flow was $813.7 million, up 24%. 2026 guidance midpoints were raised to total revenues of $14,800 million and adjusted EBITDA of $4,500 million, excluding Pacira.

Investments and deals

Pacira BioSciences acquisition
Definitive agreement at $36.50 per share in cash, an aggregate equity value of $1.65 billion, adding EXPAREL and ZILRETTA; closing expected by end of November 2026, with more than $50 million of annual cost synergies by end of 2028.
Aculys Pharma
Acquired October 15, 2025 for $35.0 million upfront for Japanese rights to pitolisant and Spydia.
Idorsia assets
$350 million upfront in March 2024 for selatogrel and cenerimod, amended in February 2025 to add Asian cenerimod rights.
Patch capacity
The estradiol patch plant moved to 24/7 operation, a packaging line is being added and expansion outside Vermont is under study.
Capital expenditure
$378.8 million in 2025, with $350 million to $450 million expected in 2026.

Challenges and risks

Indian manufacturing compliance
The Indore warning letter and import alert bar 11 products from the U.S., and the FDA classified the Nashik plant Official Action Indicated; manufacturing there is suspended until an expected Q1 2027 restart, costing approximately $100 million of revenue per quarter.
Pricing pressure
Government price reductions in Japan and Australia, volume-based procurement in China and more hospital-channel pressure expected in 2026.
Loss of exclusivity
Possible mid-2027 loss of exclusivity for AMITIZA in Japan and the full-year effect of isosulfan blue's LOE are flagged as 2027 headwinds.
Restructuring execution
The enterprise-wide strategic review and workforce reduction carry execution risk, alongside dependence on a few third-party API suppliers.

What leadership says

“we believe we have entered a new phase of sustained growth for Viatris”

Scott A. Smith, CEO · Q3 2026 earnings call, 5 November 2026

“Our third-quarter results reflect strong execution and reinforce our confidence in the growth trajectory of our business”

Scott A. Smith, CEO · Q3 2026 earnings release, 5 November 2026

“We've merged two companies, divested four major businesses, stabilized and returned the base business to growth”

Scott A. Smith, CEO · Investor Event 2026, March 2026

“operational momentum across our higher-margin businesses and continued focus on cost discipline”

Paul Campbell, Interim CFO · Q3 2026 earnings release, 5 November 2026

Where a supplier can help

Quality remediation in India
The Nashik and Indore remediation challenge creates needs for quality systems, compliance consulting, validation and data-integrity tools.
Contract manufacturing and API supply
Supply constraints and dependence on a few API suppliers make second-source CDMOs and API makers relevant, as does patch capacity expansion.
Transformation office savings
The approximately $400 million net savings target across COGS and SG&A fits procurement, automation and shared-services providers.
Launch and integration support
Launching fast-acting meloxicam, Gwyn Lo and RYZUMVI and integrating Pacira's U.S. team point to commercial, medical affairs and post-merger integration services.
Technology and data modernisation
The Modernize for Sustainable Growth imperative covers technology, data and talent, an entry point for IT, analytics and HR platforms.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Viatris?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Viatris

What does Viatris do?

Viatris makes and sells generics, established brands such as Lipitor and Viagra, and innovative medicines, supplying approximately 1 billion patients a year in more than 165 countries and territories.

What is Viatris's revenue?

Total revenues were $14,299.9 million in 2025; 2026 guidance is $14,700 million to $14,900 million, excluding Pacira.

How many employees does Viatris have?

More than 30,000 according to the 2025 10-K, before a planned workforce reduction of up to approximately 10%.

Who leads Viatris?

Scott A. Smith is CEO, Paul Campbell is Interim CFO and Melina Higgins chairs the board.

What is Viatris's strategy?

Drive the base business, fuel the innovative portfolio and modernize for sustainable growth, aiming for 5%-6% revenue growth and more than $3 billion of annual free cash flow by 2030.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)